Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating OverviewBusiness Wire • 02/26/25
Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock?Zacks Investment Research • 02/13/25
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025Business Wire • 02/12/25
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised)Zacks Investment Research • 01/16/25
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline GoalsZacks Investment Research • 01/15/25
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/14/25
Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett SyndromeBusiness Wire • 01/14/25
Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025Business Wire • 12/19/24
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 MillionBusiness Wire • 12/11/24
ACAD Signs License Deal With Saniona for Rights to Neurology DrugZacks Investment Research • 11/27/24
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711Business Wire • 11/26/24
Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue GrowthZacks Investment Research • 11/07/24
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call TranscriptSeeking Alpha • 11/07/24
Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue EstimatesZacks Investment Research • 11/06/24
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating OverviewBusiness Wire • 11/06/24
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 MillionBusiness Wire • 11/05/24
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 10/30/24
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024Business Wire • 10/17/24
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett SyndromeBusiness Wire • 10/16/24